New antibody drug ADCX-020 enters first human trials for advanced cancers

NCT ID NCT07238075

Recruiting now Disease control Sponsor: Adcytherix SAS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called ADCX-020 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody drug conjugate designed to deliver cancer-killing agents directly to tumor cells. The study will first find the safest dose, then test that dose in different cancer types to see if it shrinks tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer Drug-Related Side Effects and Adverse Reactions metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANCY ADVANCED SOLID CANCERS METASTATIC SOLID TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Blacktown Hospital
RECRUITING

Sydney, New South Wales, 2148, Australia
Cancer Research SA
RECRUITING

Adelaide, South Australia, 5000, Australia
Linear Clinical Research
RECRUITING

Nedlands, Western Australia, 6009, Australia
Macquarie University
RECRUITING

Sydney, New South Wales, 2109, Australia
START Barcelona
RECRUITING

Barcelona, Barcelona, 08023, Spain
START Madrid CIOCC
RECRUITING

Madrid, Madrid, 28050, Spain
START Madrid FJD
RECRUITING

Madrid, Madrid, 28040, Spain
Sunshine Coast University Private Hospital
RECRUITING

Birtinya, Queensland, 4575, Australia
Tasman Oncology Research
RECRUITING

Southport, Queensland, 4215, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.